



SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology



April 8-9, 2023 Hybrid congress

Name	Joong-Won PARK
Affiliation	National Cancer Center Korea
Country	Republic of Korea
Major Field	Hepatology

Educational Background

1977.3-1984.2 Graduate from Seoul National University College of Medicine, Seoul, Korea

1993.3-1996.2 Doctor of Philosophy in Medicine (Mentor; Prof. CY Kim), Seoul National University, Seoul, Korea

Professional Experience

2009-present Principal Scientist, Hepatologist, National Cancer Center Research Institution and Hospital, Korea

2021-present Head, Onco-Innovation Unit, National Center Center Korea

2014-present Professor, Graduate School of Cancer Science and Policy, National Cancer Center, Korea

2009-2011 Head, Division of Translational and Clinical Research, National Cancer Center Research Institute, Korea

2002-2010 Head, Center for Liver Cancer, National Cancer Center, Korea

Other Experience and Professional Memberships

President of Korea Liver Cancer Association

Member of the National Academy of Medicine of Korea

Chairman of Committee, KLCA (KLCSG)-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Chairman of Scientific Committee, APPLE Association

Member of Governing Board, ILCA

Member of Guideline Committee, 2013 ILCA practice guideline for the management of intrahepatic cholangiocarcinoma

Chairman of Revision Committee, 2011 KASL, Korea Practice guideline for the management of Chronic Hepatitis B

Chairman of Scientific Committee, 2008 Seoul Meeting of Asian-Pacific Association for the Study of the Liver (APASL)

Main Scientific Publications

1. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. Clin Mol Hepatol. 2022; 28(4): 583-705 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2. Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW. J Hepatol. 2021 Mar;74(3):603-612. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.

3. Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. J Hepatol 2019 Apr;70(4):684-691. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular



SIDDS 2023

Seoul International Digestive Disease Symposium 2023

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 8-9, 2023 Hybrid congress



carcinoma: a phase III STAH trial.

4. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB,..Park JW,... Kelley RK. N Engl J Med. 2018 Jul 5;379(1):54-63. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.